Arquivos brasileiros de oftalmologia · 2015
Preoperative tranilast as adjunctive therapy to primary pterygium surgery with a 1-year follow-up.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almeida Junior Gildásio C, Arakawa Luciano, Santi Neto Dalísio de, Cury Patrícia Maluf, Lima Filho Acácio A S, Sousa Sidney J F, Alves Milton R, Azoubel Reinaldo
Аннотация
PURPOSE: To determine the efficacy of tranilast as an adjunctive therapy in conjunctival autograft.
METHODS: Twenty-nine patients were randomly allocated to the Tranilast Group (n=15) or the Control Group (n=14). The Tranilast Group received a subconjunctival injection of 0.5% tranilast 30 days prior to surgery. Conjunctival autograft was performed in both groups using fibrin sealant and 0.02% subconjunctival mitomycin C at the end of the surgery. After the resection of the pterygium, immunohistochemistry was performed with 100 cells to identify epithelial cells positive for transforming growth factor-β (TGF-β). Subjective symptoms were evaluated using a 5-point scale, and the recurrence rate was assessed.
RESULTS: Both groups showed improvements in their symptoms and similar clinical results. Compared with the Control Group, the Tranilast Group failed to show a decreased recurrence rate (p=0.59). However, the number of epithelial cells expressing TGF-β was lower in the Tranilast Group (5 cells; 95% CI: 2.56-13.15; Control Group, 16 cells, 95% CI: 11.53-24.76; p=0.01). Minimal but reversible complications, including glaucoma secondary to corticosteroids and granuloma, occurred during the study.
CONCLUSION: Tranilast was effective in decreasing the number of pterygium epithelial cells expressing TGF-β.
METHODS: Twenty-nine patients were randomly allocated to the Tranilast Group (n=15) or the Control Group (n=14). The Tranilast Group received a subconjunctival injection of 0.5% tranilast 30 days prior to surgery. Conjunctival autograft was performed in both groups using fibrin sealant and 0.02% subconjunctival mitomycin C at the end of the surgery. After the resection of the pterygium, immunohistochemistry was performed with 100 cells to identify epithelial cells positive for transforming growth factor-β (TGF-β). Subjective symptoms were evaluated using a 5-point scale, and the recurrence rate was assessed.
RESULTS: Both groups showed improvements in their symptoms and similar clinical results. Compared with the Control Group, the Tranilast Group failed to show a decreased recurrence rate (p=0.59). However, the number of epithelial cells expressing TGF-β was lower in the Tranilast Group (5 cells; 95% CI: 2.56-13.15; Control Group, 16 cells, 95% CI: 11.53-24.76; p=0.01). Minimal but reversible complications, including glaucoma secondary to corticosteroids and granuloma, occurred during the study.
CONCLUSION: Tranilast was effective in decreasing the number of pterygium epithelial cells expressing TGF-β.
Предметные рубрики MeSH
AdultAutograftsConjunctivaEpithelial CellsFemaleFibrin Tissue AdhesiveFollow-Up StudiesHumansInjections, IntraocularMaleMiddle AgedMitomycinPostoperative PeriodPreoperative CareProspective StudiesPterygiumRecurrenceSecondary PreventionTransforming Growth Factor betaTransplantation, AutologousTreatment Outcomeortho-Aminobenzoates